Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

S1612-A Randomized Phase II/III Trial of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older

Purpose of this study is to compare any good and bad effects of using different new treatment options to one of the current standard treatment options given for patients with AML or MDS who cannot tolerate or do not want to get intensive chemotherapy.
Daniel Ward at dward1@pennstatehealth.psu.edu or 610-378-2336
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03092674
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Untreated AML or MDS-EB-2
Patients must be ≥ 60 years of age
Patients must have disease present in the blood or bone marrow
Exclusion Criteria:
Patients with acute promyelocytic leukemia (APL), biphenotypic leukemia, blastic
Patients must not be known to have AML in the CNS.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Reading, PA